Close Window

Digital Look Email A Friend

New research supports mode of action in Faron's 'MATINS' study

Published by Josh White on 3rd June 2021

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the publication of research supporting the immunotherapeutic blockade of 'Clever-1' to activate anti-tumour immune responses in advanced cancer patients on Thursday.

URL: http://www.digitallook.com/dl/news/story/31893974/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.